Literature DB >> 1945412

Structural and functional analysis of the regulatory sequences of the ets-1 gene.

T Oka1, A Rairkar, J H Chen.   

Abstract

The ets-1 gene is a human homolog of the oncogene v-ets of avian acute leukemia virus E26. The ets-1 gene is preferentially expressed in lymphoid cells. To understand the regulation of the ets-1 gene expression the regulatory sequences of this gene were identified and isolated. The promoter is found to be functioning in the lymphoid cell line Daudi and the erythromyeloid cell line K562 but not in the promyelocytic cell line HL60. Sequence analysis indicates that the ets-1 promoter does not contain the TATA or CAT box. It contains multiple transcription initiation sites in a tight cluster. The promoter contains one binding site each for AP1 and AP2. It has one definitive and five presumptive sp1-binding sites. In addition, the ets-1 promoter contains one ets-1 protein-binding site. Functional analysis has shown that c-jun enhances the activity of the ets-1 promoter, whereas the combination of c-fos and c-jun expressions has no synergistic effect. The expression of exogenous AP2 and ets-1 also enhances the activity of the ets-1 promoter. These results suggest that the AP1, AP2 and ets-1 proteins have a positive regulatory effect. The presence of the ets-1 protein-binding site indicates the existence of an autoregulatory mechanism for the expression of the ets-1 gene. Our results suggested that the presence of a negative regulatory element upstream of the region where most of the positive regulators are located.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1945412

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The transcription factor E26 transformation-specific sequence-1 mediates neointima formation in arteriovenous fistula.

Authors:  Wenguang Feng; Phillip Chumley; Michael Allon; James George; David W Scott; Rakesh P Patel; Silvio Litovsky; Edgar A Jaimes
Journal:  J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 10.121

2.  On the role of AP2 in epithelial-specific gene expression.

Authors:  T Magnaldo; R G Vidal; M Ohtsuki; I M Freedberg; M Blumenberg
Journal:  Gene Expr       Date:  1993

3.  Silencer elements controlling the B29 (Igbeta) promoter are neither promoter- nor cell-type-specific.

Authors:  C S Malone; S A Omori; R Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

4.  EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Authors:  Janyaporn Phuchareon; Frank McCormick; David W Eisele; Osamu Tetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

5.  Identification and dissection of a key enhancer mediating cranial neural crest specific expression of transcription factor, Ets-1.

Authors:  Meyer Barembaum; Marianne E Bronner
Journal:  Dev Biol       Date:  2013-08-19       Impact factor: 3.582

6.  The two functionally distinct amino termini of chicken c-ets-1 products arise from alternative promoter usage.

Authors:  P Crepieux; D Leprince; A Flourens; O Albagli; E Ferreira; D Stéhelin
Journal:  Gene Expr       Date:  1993

7.  Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes.

Authors:  Abdelhamid Liacini; Judith Sylvester; Wen Qing Li; Muhammad Zafarullah
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

Review 8.  ETS-targeted therapy: can it substitute for MEK inhibitors?

Authors:  Osamu Tetsu; Frank McCormick
Journal:  Clin Transl Med       Date:  2017-05-02

9.  ETS1, ELK1, and ETV4 Transcription Factors Regulate Angiopoietin-1 Signaling and the Angiogenic Response in Endothelial Cells.

Authors:  Sharon Harel; Veronica Sanchez; Alaa Moamer; Javier E Sanchez-Galan; Mohammad N Abid Hussein; Dominique Mayaki; Mathieu Blanchette; Sabah N A Hussain
Journal:  Front Physiol       Date:  2021-07-26       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.